Search
Pirbuterol
go.drugbank.com/drugs/DB01291ApprovedWithdrawnPirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is reco...
Gaboxadol
go.drugbank.com/drugs/DB06554InvestigationalGaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing … It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives.
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]
Droxicam
go.drugbank.com/drugs/DB09215ApprovedWithdrawnDroxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of DB00554. It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884Approved[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.
Anastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigational[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and
Pepinemab
go.drugbank.com/drugs/DB15155InvestigationalPepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).
Cefoperazone
go.drugbank.com/drugs/DB01329ApprovedInvestigationalWithdrawnIt is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis
Enmetazobactam
go.drugbank.com/drugs/DB18716ApprovedInvestigational[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL. … [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.
Pagoclone
go.drugbank.com/drugs/DB04903InvestigationalIt is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures